Derms on Drugs

The Derms on Drugs bring in a heavy hitter straight out of silicon valley to talk AI and the future of dermatology.  Dr. Faranak Kamangar is a Board Certified Dermatologist who founded, built and continues to improve DermGPT - a derm specific LLM that just outperformed ChatGPT in a head-to-head contest judged by dermatologists!  As usual, we'll answer the questions you didn't know you had (well, maybe you knew you had some of these):
Is AI going to make our lives easier or is it going to replace us?
How good is AI at answering patient questions?
Will patients accept "AI Providers"?
How can you start levering AI now to make your life better?
What AI tools are out there to start using right now?
Are AI scribes all that great?

The Derms on Drugs give the definitive answer to the age old question:  What came first, the chicken or the egg?  You'll have to listen to find out.  

What's a Mazotti Reaction and why do you care?
How do JAK inhibitors compare to dupilumab for treating prurigo nodularis?
What's a cheap, easy, safe, effective treatment for palmoplantar pustulosis?
Can a steroid nasal spray help for Chronic Spontaneous Urticaria?
Do biologics reduce infection risk in AD more than JAK Inhibitors and why?
How does superficial radiation therapy compare to Mohs for skin cancer?
Dermal hyperpigmentation is impossible to treat - can isotretinoin help?
Cheilitis drives derms and patients nuts - what's the new, cheap, easy way to help?

Get ready for a no-nonsense tour-de-force of practical application in the latest derm literature. Pipeline drugs, new approvals, brand names, generics—and HS data you’re better off ignoring (we’ll tell you why).
 
In this episode:
·       Leqselvi: the newest JAK for alopecia areata—actually different, or more of the same?
·       HS & spondyloarthritis: are you screening… should you be?
·       JAKs and the heart: are all cardiovascular risks created equal?
·       “2/3 HS remission” headlines: why this data shouldn’t change your practice
·       Tirbanibulin + cryo for AKs: combo win or marketing math?
·       Hydrochlorothiazide & skin cancer: do you really need that conversation?
·       Oral minoxidil + Olumiant: synergy or wishful thinking in AA?
·       OX40/OX40L blockers: exciting pathway—new hope or new hype?
 
Fast. Practical. Slightly skeptical (for good reason).

If you prescribe, counsel, or roll your eyes at bad data—this one’s for you.

Listening this week could save your life (well, at least your kidneys).  Find out what common ingredient in keratin treatments you (and your friends, family and patients) NEED to avoid.  But there's a lot more than that packed into this week's episode.  As always, the Derms on Drugs bring the goods on the latest questions that the literature is answering:
-Is isotretinoin making kids short?  
-Is Dupixent making them tall?  
-What is "transcutaneous auricular vagus nerve stimulation" and which common but difficult derm disease does it help with?  
-What OTC supplement makes NBUVB work better for vitiligo?  
-What oral drug can you add to isotretinoin to make it work even better?  
-Does oral tranexamic acid increase the risk of blood clots when used in dermatology?
-How well does Opzelura work for hidradenitis suppurativa?
-Do Humira biosimilars work as well as Humira in hidradenitis suppurativa?
-What common statistical technique used by pharma is total BS?
-Which ingredient in 'keratin treatments" is causing kidney failure and kidney stones?

Admit it—bad hair days are the worst. Now imagine every day is one. Alopecia’s psychological impact is way deeper (and more surprising) than most people think. This week, the Derms on Drugs sit down with Harvard’s Dr. Maryanne Makredes Senna to unpack the mental side of AA—and then dive into what to do when a JAK inhibitor just… doesn’t JAK. As always, we’re answering the questions you didn’t even know you had.
Here’s what we’re tackling:
What hits harder on anxiety and depression—scarring or non-scarring alopecia?

How tightly does AA severity track with psychological burden?

How should you approach the mental health effects of AA?
(Yes, you should ask. No, you shouldn’t be the one treating—here’s how to bridge patients to the right therapists.)

And what do you do when a JAK Inhibitor isn’t giving you the results you hoped for?